Fulgent Genetics Inc (FLGT)

$20.78

-0.29

(-1.38%)

Market is closed - opens 7 PM, 15 Apr 2024

Insights on Fulgent Genetics Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 84.68M → 70.50M (in $), with an average decrease of 16.8% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -11.22M → -128.14M (in $), with an average decrease of 447.2% per quarter

  • Vs IQV

    In the last 1 year, Iqvia Holdings Inc. has given 16.9% return, outperforming this stock by 49.5%

  • Vs TMO

    In the last 3 years, Thermo Fisher Scientific, Inc. has given 9.4% return, outperforming this stock by 86.4%

Performance

  • $20.63
    $21.07
    $20.78
    downward going graph

    0.72%

    Downside

    Day's Volatility :2.09%

    Upside

    1.38%

    downward going graph
  • $20.66
    $44.09
    $20.78
    downward going graph

    0.58%

    Downside

    52 Weeks Volatility :53.14%

    Upside

    52.87%

    downward going graph

Returns

PeriodFulgent Genetics IncSector (Health Care)Index (Russel 2000)
3 Months
-21.47%
-1.1%
0.0%
6 Months
-17.31%
6.7%
0.0%
1 Year
-32.66%
3.2%
-0.7%
3 Years
-77.02%
15.2%
-21.6%

Highlights

Market Capitalization
631.7M
Book Value
$38.31
Earnings Per Share (EPS)
-5.63
PEG Ratio
1.32
Wall Street Target Price
26.67
Profit Margin
-58.03%
Operating Margin TTM
-47.5%
Return On Assets TTM
-3.47%
Return On Equity TTM
-14.58%
Revenue TTM
289.2M
Revenue Per Share TTM
9.71
Quarterly Revenue Growth YOY
4.1000000000000005%
Gross Profit TTM
366.9M
EBITDA
-46.6M
Diluted Eps TTM
-5.63
Quarterly Earnings Growth YOY
-0.99
EPS Estimate Current Year
-1.06
EPS Estimate Next Year
-0.76
EPS Estimate Current Quarter
-0.29
EPS Estimate Next Quarter
-0.23

Analyst Recommendation

Buy
    75%Buy
    25%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Fulgent Genetics Inc(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
7
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 28.34%

Current $20.78
Target $26.67

Company Financials

FY18Y/Y Change
Revenue
21.4M
↑ 14.03%
Net Income
-4.5M
↑ 68.7%
Net Profit Margin
-21.02%
↓ 6.81%
FY19Y/Y Change
Revenue
32.5M
↑ 52.31%
Net Income
366.0K
↓ 108.15%
Net Profit Margin
1.13%
↑ 22.15%
FY20Y/Y Change
Revenue
421.7M
↑ 1196.46%
Net Income
214.3M
↑ 58454.64%
Net Profit Margin
50.82%
↑ 49.69%
FY21Y/Y Change
Revenue
992.6M
↑ 135.37%
Net Income
104.3M
↓ 51.31%
Net Profit Margin
10.51%
↓ 40.31%
FY22Y/Y Change
Revenue
619.0M
↓ 37.64%
Net Income
143.4M
↑ 37.44%
Net Profit Margin
23.17%
↑ 12.66%
FY23Y/Y Change
Revenue
289.2M
↓ 53.27%
Net Income
-167.8M
↓ 217.03%
Net Profit Margin
-58.03%
↓ 81.2%
Q3 FY22Q/Q Change
Revenue
105.7M
↓ 15.71%
Net Income
1.3M
↓ 88.36%
Net Profit Margin
1.27%
↓ 7.93%
Q4 FY22Q/Q Change
Revenue
67.7M
↓ 35.92%
Net Income
-24.1M
↓ 1892.7%
Net Profit Margin
-35.56%
↓ 36.83%
Q1 FY23Q/Q Change
Revenue
66.2M
↓ 2.27%
Net Income
-15.8M
↓ 34.17%
Net Profit Margin
-23.95%
↑ 11.61%
Q2 FY23Q/Q Change
Revenue
67.9M
↑ 2.55%
Net Income
-11.2M
↓ 29.15%
Net Profit Margin
-16.55%
↑ 7.4%
Q3 FY23Q/Q Change
Revenue
84.7M
↑ 24.81%
Net Income
-13.1M
↑ 16.72%
Net Profit Margin
-15.48%
↑ 1.07%
Q4 FY23Q/Q Change
Revenue
70.5M
↓ 16.75%
Net Income
-128.1M
↑ 877.71%
Net Profit Margin
-181.76%
↓ 166.28%
FY18Y/Y Change
Total Assets
55.0M
↓ 3.4%
Total Liabilities
2.7M
↓ 6.15%
FY19Y/Y Change
Total Assets
88.8M
↑ 61.33%
Total Liabilities
6.0M
↑ 117.81%
FY20Y/Y Change
Total Assets
700.5M
↑ 689.2%
Total Liabilities
131.1M
↑ 2092.24%
FY21Y/Y Change
Total Assets
1.3B
↑ 82.55%
Total Liabilities
112.8M
↓ 13.91%
FY22Y/Y Change
Total Assets
1.4B
↑ 8.39%
Total Liabilities
116.2M
↑ 2.96%
FY23Y/Y Change
Total Assets
1.3B
↓ 8.15%
Total Liabilities
139.8M
↑ 20.35%
Q3 FY22Q/Q Change
Total Assets
1.4B
↓ 3.82%
Total Liabilities
124.4M
↓ 17.59%
Q4 FY22Q/Q Change
Total Assets
1.4B
↓ 1.4%
Total Liabilities
116.2M
↓ 6.6%
Q1 FY23Q/Q Change
Total Assets
1.4B
↓ 0.67%
Total Liabilities
107.8M
↓ 7.17%
Q2 FY23Q/Q Change
Total Assets
1.4B
↓ 1.61%
Total Liabilities
91.3M
↓ 15.39%
Q3 FY23Q/Q Change
Total Assets
1.4B
↑ 0.28%
Total Liabilities
96.6M
↑ 5.82%
Q4 FY23Q/Q Change
Total Assets
1.3B
↓ 6.28%
Total Liabilities
139.8M
↑ 44.8%
FY18Y/Y Change
Operating Cash Flow
-675.0K
↓ 150.71%
Investing Cash Flow
950.0K
↓ 146.36%
Financing Cash Flow
15.0K
↓ 101.95%
FY19Y/Y Change
Operating Cash Flow
5.5M
↓ 917.33%
Investing Cash Flow
-29.0M
↓ 3157.47%
Financing Cash Flow
28.8M
↑ 191733.33%
FY20Y/Y Change
Operating Cash Flow
140.6M
↑ 2448.99%
Investing Cash Flow
-326.4M
↑ 1023.87%
Financing Cash Flow
261.3M
↑ 807.91%
FY21Y/Y Change
Operating Cash Flow
538.6M
↑ 282.98%
Investing Cash Flow
-546.5M
↑ 67.43%
Financing Cash Flow
85.4M
↓ 67.31%
FY22Y/Y Change
Operating Cash Flow
253.5M
↓ 52.93%
Investing Cash Flow
-261.3M
↓ 52.19%
Financing Cash Flow
-77.1M
↓ 190.32%
Q3 FY22Q/Q Change
Operating Cash Flow
20.8M
↑ 86.73%
Investing Cash Flow
44.3M
↓ 120.73%
Financing Cash Flow
-35.5M
↑ 217.99%
Q4 FY22Q/Q Change
Operating Cash Flow
33.2M
↑ 59.83%
Investing Cash Flow
-92.6M
↓ 309.08%
Financing Cash Flow
-29.6M
↓ 16.55%
Q1 FY23Q/Q Change
Operating Cash Flow
-7.9M
↓ 123.81%
Investing Cash Flow
-4.4M
↓ 95.3%
Financing Cash Flow
-1.1M
↓ 96.28%
Q2 FY23Q/Q Change
Operating Cash Flow
9.7M
↓ 223.14%
Investing Cash Flow
-1.1M
↓ 74.83%
Financing Cash Flow
-16.3M
↑ 1376.75%

Technicals Summary

Sell

Neutral

Buy

Fulgent Genetics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Fulgent Genetics Inc
Fulgent Genetics Inc
-5.93%
-17.31%
-32.66%
-77.02%
208.31%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
-6.04%
15.89%
3.38%
-5.8%
121.02%
Agilent Technologies Inc.
Agilent Technologies Inc.
-4.58%
26.22%
0.39%
5.59%
75.04%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
-3.24%
15.7%
-3.97%
14.33%
103.64%
Danaher Corp.
Danaher Corp.
-3.79%
14.02%
-6.18%
-1.09%
83.87%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
-7.31%
17.72%
15.6%
9.39%
66.03%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Fulgent Genetics Inc
Fulgent Genetics Inc
7.49
NA
1.32
-1.06
-0.15
-0.03
NA
38.31
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
50.21
50.21
4.81
11.13
0.81
0.23
NA
17.88
Agilent Technologies Inc.
Agilent Technologies Inc.
34.49
34.49
2.77
5.5
0.21
0.08
0.01
21.12
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
37.18
37.18
2.85
21.56
0.13
0.05
0.0
120.87
Danaher Corp.
Danaher Corp.
43.44
43.44
3.2
7.62
0.08
0.04
0.0
72.36
Iqvia Holdings Inc.
Iqvia Holdings Inc.
32.8
32.8
1.4
11.11
0.23
0.05
NA
33.67
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Fulgent Genetics Inc
Fulgent Genetics Inc
Buy
$631.7M
208.31%
7.49
-58.03%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$41.9B
121.02%
50.21
23.08%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$42.2B
75.04%
34.49
18.35%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$219.0B
103.64%
37.18
13.99%
Danaher Corp.
Danaher Corp.
Buy
$182.1B
83.87%
43.44
19.94%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$43.6B
66.03%
32.8
9.06%

Institutional Holdings

  • BlackRock Inc

    12.58%
  • Dimensional Fund Advisors, Inc.

    4.84%
  • Vanguard Group Inc

    4.74%
  • State Street Corporation

    2.72%
  • Geode Capital Management, LLC

    1.55%
  • Park West Asset Management LLC

    1.42%

Company Information

mission developing flexible and affordable genetic testing that improves the everyday lives of those around us. founded in 2011, fulgent began with two simple ideas; flexibility and affordability. today, we strive to create the most effective and wide ranging tests on the market. all of this is done in the pursuit of bettering the everyday lives of our customers. we shine brightest when meaningful relationships, passion, and purpose come together. why fulgent? we are committed to working side-by-side with every one of our clients. this is essential to a strong and successful relationship and is our core way of doing business. we have collaborated with some of the top clinicians in our field who have assisted us in creating our panels, report formatting, and improvements to our website. our approach has always been simple: provide testing based on the specific needs of clinicians and their patients. customer support our support philosophy has always been simple: answer our client's ques

Organization
Fulgent Genetics Inc
Employees
1184
CEO
Mr. Ming Hsieh
Industry
Health Services

FAQs